Andrew Witty was born 22 August 1964 in Nantwich, England, and earned a bachelor's degree in economics from the University of Nottingham.
Andrew Witty was born 22 August 1964 in Nantwich, England, and earned a bachelor's degree in economics from the University of Nottingham. ◦
He joined Glaxo UK in 1985 as a management trainee, was appointed president of Pharmaceuticals Europe in January 2003, and became GSK's CEO in May 2008, succeeding Jean-Pierre Garnier. ◦
He was knighted in the 2012 New Year Honours for services to the economy and the pharmaceutical industry, and served as Chancellor of the University of Nottingham from 2013 to 2017. ◦
After GSK, Witty became CEO of UnitedHealth Group's Optum division in July 2018, president of UnitedHealth in November 2019, and CEO of UnitedHealth Group from February 2021 until he stepped down in May 2025 for 'personal reasons'; he also assisted the WHO with vaccine development efforts from April to December 2020. ◦
Witty has articulated that the mission of UnitedHealth Group is to improve the system for everybody and help people live healthier lives. ◦
He framed UnitedHealth's strategy as getting more people into high-quality value-based care and keeping them healthy in the first place, arguing the system needs to be less confusing, less complex and less costly. ◦
He identified price as the root cause of system costs, noting that price more than utilization drives system costs higher. ◦
He has articulated a consumer-experience standard for healthcare, stating that people's health interaction should be as intuitive and seamless as every other aspect of their lives—banking, shopping, streaming. ◦
On reforming the industry, Witty said there are so many areas that can be enhanced, reworked, reengineered or even scrapped to make the health system better, and that ultimately, improving healthcare means addressing the root cause of healthcare costs. ◦
He stressed cooperation over competition in reform, emphasizing the criticality of collaboration to try and design something, not just for one company, but for all companies, not just for one patient, but for all patients. ◦
He rejected the premise that affordability and innovation are in tension, stating there is a way you can create real impact in the developing world and not sacrifice innovation, achieved through flexible pricing and a flexible approach to intellectual property. ◦
He warned that it will be really harmful to everybody if someone starts putting barriers up, adding that we absolutely rely on a global trading environment. ◦
In a December 2024 New York Times op-ed, Witty conceded the US health system does not work as well as it should and made the admission that no one would design a system like the one we have. ◦
As GSK CEO in February 2009, Witty pledged to make a major change in the way GSK pharmaceuticals are priced in an attempt to make vital drugs more affordable in countries with the lowest incomes, and proposed that GSK place certain patents in a pool so they were freely available to others in the search for new drugs. ◦
He has defended pharmacy benefit managers as cost-control mechanisms, stating they play a vital role in holding these prices down, which is why drug companies and their allies have spent the past several years attacking them. ◦
He acknowledged that some areas like claims, where people get frustrated about how long it takes for a claim to process or maybe some confusion goes on in that, are key areas to continue to work hard at to improve. ◦
Regarding succession at GSK, he said handing the company to Emma Walmsley was going to be an exciting period, noting that not everything is going to work, there will be some failures and some successes. ◦
Witty applies a root-cause framework to healthcare costs, arguing that price more than utilization drives system costs higher and that improving healthcare means addressing the root cause of healthcare costs. ◦ ◦
He uses a consumer-experience mental model, asserting that people's health interaction should be as intuitive and seamless as every other aspect of their lives—banking, shopping, streaming. ◦
He views the business through a balanced-innovation lens, stating that GSK demonstrated the capability of doing balanced business to innovate and to drive access, and that 25 pc of sales comes from products less than three years old. ◦
He sees global trade as an interconnected system, warning that it will be really harmful to everybody if someone starts putting barriers up and that we absolutely rely on a global trading environment. ◦
He has described health system improvement in terms of redesign, stating there are so many areas that can be enhanced, reworked, reengineered or even scrapped to make the health system better. ◦
Witty has extensive experience in the pharmaceutical industry, having joined Glaxo UK in 1985 and eventually becoming GSK's CEO, and was knighted for services to the economy and the pharmaceutical industry. ◦
He assisted the WHO with vaccine development efforts from April to December 2020. ◦
He has led major health insurance and managed care organizations, having served as CEO of UnitedHealth Group and its Optum division, and has spoken about the role of pharmacy benefit managers in controlling drug prices. ◦ ◦
He has demonstrated knowledge of value-based care, framing UnitedHealth's strategy as getting more people into high-quality value-based care and keeping them healthy in the first place. ◦
He has engaged with global pricing and intellectual property frameworks, proposing patent pools and flexible pricing to balance innovation and access. ◦ ◦
Witty uses direct concessions about systemic failures, as when he wrote that the US health system does not work as well as it should and that no one would design a system like the one we have. ◦
He employs consumer-experience analogies, stating that people's health interaction should be as intuitive and seamless as every other aspect of their lives—banking, shopping, streaming. ◦
He grounds arguments in comparative data, noting that one drug, which costs $900 in the U.S. costs about one-tenth of that in Europe. ◦
He acknowledges operational friction directly, stating that some areas like claims, where people get frustrated about how long it takes for a claim to process or maybe some confusion goes on in that, are key areas to continue to work hard at to improve. ◦
He closes appeals with collaborative framing, writing that UnitedHealth was willing to partner with anyone, as we always have, to improve the health system. ◦
Witty's reputation as a reformer sits in tension with his record: as GSK CEO he positioned the company on access and transparency, yet in 2013 his own China business was caught in a bribery scandal that he attributed to senior executives acting outside our processes and controls. ◦
The same tension reappeared at UnitedHealth: Witty championed lower-cost, value-based care while his 2023 compensation reached $23.5 million, a 352-to-1 CEO-to-worker pay ratio at the largest US health insurer. ◦
Witty has emphasized the criticality of collaboration to try and design something, not just for one company, but for all companies, not just for one patient, but for all patients. ◦
He wrote that UnitedHealth was willing to partner with anyone, as we always have, to improve the health system. ◦
He has acknowledged that some areas like claims, where people get frustrated about how long it takes for a claim to process or maybe some confusion goes on in that, are key areas to continue to work hard at to improve. ◦
On succession and risk-taking, he said that handing GSK to Emma Walmsley was going to be an exciting period, noting that not everything is going to work, there will be some failures and some successes. ◦